Charles Heidelberger: Fluorinated Pyrimidines and Their Nucleosides. In: Antineoplastic and Immunosuppressive Agents (= Handbuch der experimentellen Pharmakologie / Handbook of Experimental Pharmacology). Springer, Berlin, Heidelberg 1975, ISBN 3-642-65808-3, S.193–231, doi:10.1007/978-3-642-65806-8_12.
D. Meulendijks, E. A. Rozeman, A. Cats, K. Sikorska, M. Joerger: Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies. In: The Pharmacogenomics Journal. Band17, Nr.5, Oktober 2017, S.441–451, doi:10.1038/tpj.2016.81.
Ruolan Han, Yin M Yang, Joerg Dietrich, Anne Luebke, Margot Mayer-Pröschel, Mark Noble: Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. In: Journal of Biology. 7, 2008, S. 12, doi:10.1186/jbiol69.
H. Koenig, A. Patel: The acute cerebellar syndrome in 5-fluorouracil chemotherapy: a manifestation of fluoroacetate intoxication. In: Neurology. Band20, Nr.4, April 1970, S.416, PMID 5535078.
Kazumasa Yamashita, Hideaki Yada, Toshihiko Ariyoshi: Neurotoxic effects of alpha-fluoro-beta-alanine (FBAL) and fluoroacetic acid (FA) on dogs. In: The Journal of Toxicological Sciences. Band29, Nr.2, Mai 2004, S.155–166, PMID 15206584.
M. Arellano, M. Malet-Martino, R. Martino, T. Spector: 5-Ethynyluracil (GW776): effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxypropionic acid in the isolated perfused rat liver model. In: British Journal of Cancer. Band76, Nr.9, 1997, S.1170–1180, PMID 9365165, PMC 2228116 (freier Volltext).
M. Arellano, M. Malet-Martino, R. Martino, P. Gires: The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate. In: British Journal of Cancer. Band77, Nr.1, 1998, S.79–86, PMID 9459149, PMC 2151255 (freier Volltext).
